tetano
Editor, Senior Moderator
Neurol Sci
. 2024 May 9.
doi: 10.1007/s10072-024-07578-6. Online ahead of print. Multiple sclerosis and COVID-19: a northern China survey
Qian Guo[SUP] #[/SUP][SUP] 1 [/SUP], Tianwei Wang[SUP] #[/SUP][SUP] 2 [/SUP], Yusen Huang[SUP] 1 [/SUP], Fangruyue Wang[SUP] 3 [/SUP], Pingping Hao[SUP] 1 [/SUP], Le Fang[SUP] 4 [/SUP]
Affiliations
Background: There is insufficient data on severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) infection in Chinese patients with multiple sclerosis (pwMS). This study aims to explore the manifestation of pwMS during the Coronavirus disease 2019 (COVID-19) pandemic and the effect of SARS-CoV-2 infection on the prognosis of MS in northern China.
Methods: In this cross-sectional study, an online self-administered questionnaire and telephone interviews were conducted among pwMS of northern China. Clinical correlation of SARS-CoV-2 infection since the onset of the COVID-19 pandemic in northern China was analyzed.
Results: 164 patients with an average age of 38.9 ± 12.2 years were included, of which 57.3% had a disease course ≤ 5 years. 33.5% of the patients were COVID-19 vaccinated. 87.2% received disease-modifying therapy (DMT), and the average immunotherapy duration was 1.9 ± 1.6 years. 83.5% were SARS-CoV-2 infected, 14.6% reported worsening of their original condition after infection, and 5.1% had a relapse of MS. Shorter disease course was independently related to infection risk (P = 0.046), whereas increasing age was related to aggravated behavioral symptoms (P = 0.008). However, gender, vaccination, and DMT were not associated with susceptibility or poor prognosis.
Conclusion: A shorter disease course is independently associated with an increased risk of SARS-CoV-2 infection, and age is associated with worsening disability. It seems to be safe and necessary to use DMT during the pandemic, however, the use of B cell-depletion agents should be approached with caution.
Keywords: Coronavirus disease 2019; Disease course; Disease-modifying therapy; Multiple sclerosis; Severe acute respiratory syndrome coronavirus type-2.
. 2024 May 9.
doi: 10.1007/s10072-024-07578-6. Online ahead of print. Multiple sclerosis and COVID-19: a northern China survey
Qian Guo[SUP] #[/SUP][SUP] 1 [/SUP], Tianwei Wang[SUP] #[/SUP][SUP] 2 [/SUP], Yusen Huang[SUP] 1 [/SUP], Fangruyue Wang[SUP] 3 [/SUP], Pingping Hao[SUP] 1 [/SUP], Le Fang[SUP] 4 [/SUP]
Affiliations
- PMID: 38722503
- DOI: 10.1007/s10072-024-07578-6
Background: There is insufficient data on severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) infection in Chinese patients with multiple sclerosis (pwMS). This study aims to explore the manifestation of pwMS during the Coronavirus disease 2019 (COVID-19) pandemic and the effect of SARS-CoV-2 infection on the prognosis of MS in northern China.
Methods: In this cross-sectional study, an online self-administered questionnaire and telephone interviews were conducted among pwMS of northern China. Clinical correlation of SARS-CoV-2 infection since the onset of the COVID-19 pandemic in northern China was analyzed.
Results: 164 patients with an average age of 38.9 ± 12.2 years were included, of which 57.3% had a disease course ≤ 5 years. 33.5% of the patients were COVID-19 vaccinated. 87.2% received disease-modifying therapy (DMT), and the average immunotherapy duration was 1.9 ± 1.6 years. 83.5% were SARS-CoV-2 infected, 14.6% reported worsening of their original condition after infection, and 5.1% had a relapse of MS. Shorter disease course was independently related to infection risk (P = 0.046), whereas increasing age was related to aggravated behavioral symptoms (P = 0.008). However, gender, vaccination, and DMT were not associated with susceptibility or poor prognosis.
Conclusion: A shorter disease course is independently associated with an increased risk of SARS-CoV-2 infection, and age is associated with worsening disability. It seems to be safe and necessary to use DMT during the pandemic, however, the use of B cell-depletion agents should be approached with caution.
Keywords: Coronavirus disease 2019; Disease course; Disease-modifying therapy; Multiple sclerosis; Severe acute respiratory syndrome coronavirus type-2.